NAPLES, Fla., Jan. 15, 2025 (GLOBE NEWSWIRE) — Attralus, Inc., a clinical stage biopharmaceutical company developing transformative products to improve the lives of patients with systemic amyloidosis, and Brigham and Women’s Hospital, Boston, MA, are pleased to announce the enrollment of the first patient in the Research with 124I-EVuzamitide to Elucidate Cardiac AmyLoidosis (REVEAL) study – A Phase 3 clinical trial of the investigational diagnostic imaging agent, 124I-evuzamitide (AT-01), in patients with suspected cardiac amyloidosis. The trial is designed to determine the sensitivity and specificity of 124I-evuzamitide imaging to diagnose cardiac amyloidosis. “This study seeks to add significant value for patient care,” says Dr. Sharmila Dorbala, Principal Investigator and Sponsor of the REVEAL study. “124I-evuzamitide PET/CT imaging offers an exciting opportunity to noninvasively detect various types of amyloid deposition in the heart and other organs. As cardiac amyloidosis has high morbidity and mortality, early diagnosis is crucial. With effective FDA-approved treatments now available, a scan that can definitively detect amyloidosis or exclude it would be a major step forward to reduce diagnostic delays and improve patient outcomes.”

124I-evuzamitide shown to be highly accurate for detection of cardiac amyloid across two independent investigator-initiated studies. 124I-evuzamitide detects multiple types of systemic amyloidosis. 124I-evuzamitide may be more sensitive than standard diagnostics, with cardiac uptake shown in ATTR patients who had […]